[
  {
    "ts": "2026-01-08T07:13:56+00:00",
    "headline": "Should J&J’s Nipocalimab SLE Win and OTTAVA Robot Push Require Action From Johnson & Johnson (JNJ) Investors?",
    "summary": "In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the Phase 2b JASMINE trial for systemic lupus erythematosus and moved the program into Phase 3, while also advancing its MedTech ambitions with an FDA De Novo submission for the OTTAVA robotic surgical system in general surgery. This combination of a potentially first-in-class FcRn blocker in SLE and a next-generation soft-tissue surgery robot underscores Johnson &...",
    "url": "https://finance.yahoo.com/news/j-j-nipocalimab-sle-win-071356634.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7fde2efc-ad5a-3204-ac1f-063d6c591e58",
      "content": {
        "id": "7fde2efc-ad5a-3204-ac1f-063d6c591e58",
        "contentType": "STORY",
        "title": "Should J&J’s Nipocalimab SLE Win and OTTAVA Robot Push Require Action From Johnson & Johnson (JNJ) Investors?",
        "description": "",
        "summary": "In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the Phase 2b JASMINE trial for systemic lupus erythematosus and moved the program into Phase 3, while also advancing its MedTech ambitions with an FDA De Novo submission for the OTTAVA robotic surgical system in general surgery. This combination of a potentially first-in-class FcRn blocker in SLE and a next-generation soft-tissue surgery robot underscores Johnson &...",
        "pubDate": "2026-01-08T07:13:56Z",
        "displayTime": "2026-01-08T07:13:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-nipocalimab-sle-win-071356634.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-nipocalimab-sle-win-071356634.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T08:00:00+00:00",
    "headline": "Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics",
    "summary": "Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. He",
    "url": "https://finance.yahoo.com/news/onco3r-therapeutics-appoints-lawrence-blatt-080000490.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a726c54d-9700-3de7-80fd-dfb1e1341911",
      "content": {
        "id": "a726c54d-9700-3de7-80fd-dfb1e1341911",
        "contentType": "STORY",
        "title": "Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics",
        "description": "",
        "summary": "Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. He",
        "pubDate": "2026-01-08T08:00:00Z",
        "displayTime": "2026-01-08T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/3d6ae77973984fe931847db550667c52",
          "originalWidth": 1180,
          "originalHeight": 358,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DvkRHx8M9lTA3aFztOCnfg--~B/aD0zNTg7dz0xMTgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/3d6ae77973984fe931847db550667c52.cf.webp",
              "width": 1180,
              "height": 358,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lJtfhB_tdho6MAqgGcef5Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3d6ae77973984fe931847db550667c52.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/onco3r-therapeutics-appoints-lawrence-blatt-080000490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/onco3r-therapeutics-appoints-lawrence-blatt-080000490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALGS"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T11:00:00+00:00",
    "headline": "EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology",
    "summary": "SAN MATEO, Calif., January 08, 2026--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).",
    "url": "https://finance.yahoo.com/news/epibiologics-closes-107m-series-b-110000044.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "45f1a5dd-1409-3c4b-a15e-a4fed265bff6",
      "content": {
        "id": "45f1a5dd-1409-3c4b-a15e-a4fed265bff6",
        "contentType": "STORY",
        "title": "EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology",
        "description": "",
        "summary": "SAN MATEO, Calif., January 08, 2026--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).",
        "pubDate": "2026-01-08T11:00:00Z",
        "displayTime": "2026-01-08T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/b76e839ed05029330e48724410a4fb86",
          "originalWidth": 2463,
          "originalHeight": 578,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/47tap06EQG9Bf0jOG.ubOA--~B/aD01Nzg7dz0yNDYzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b76e839ed05029330e48724410a4fb86.cf.webp",
              "width": 2463,
              "height": 578,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CEgRyuRW1ZJzK0VSNzC5.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b76e839ed05029330e48724410a4fb86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/epibiologics-closes-107m-series-b-110000044.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/epibiologics-closes-107m-series-b-110000044.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]